Bayer Grants4Apps® Dealmaker Berlin 2017

Bayer Grants4Apps® is calling all mature teams, startups and companies that have a solution ready to go. The new Dealmaker is all about quality facetime between you and Grants4Apps' experts for one full day. If there is a match, you will be invited to Berlin to pitch your solution, discuss collaboration options and close a deal. Find out, if there is a mutual interest to start a bigger journey.

Grants4Apps team has put together specific challenges, applicants are asked to address one or multiple of these challenges below. However, the team is also open for other solutions that help healthcare providers or patients, as well as products dedicated to preventing or diagnosing diseases or improving pharmaceutical processes.

The Challenges

Hemophilia

  • Empower hemophilia (bleeding disease) patients to individually adjust their treatment regimen to lead active lives.

Women's Health

  • Enabling earlier diagnosis of endometriosis.
  • Enhancing intrauterine device insertion training for providers.
  • Providing effective contraceptive counseling (face to face, remote or automated).
  • Improving comfort and experience during intrauterine device insertion for both providers & patients.
  • Simplifying the thread/placement check post-insertion of intrauterine devices.

Pulmonology

  • Improve identification of Chronic Thromboembolic Pulmonary Hypertension (CTEPH) patients.
  • Improve adherence for an oral pulmonary hypertension treatment.
  • Innovative and efficient concepts for training staff to use a drug and device combination product in an intensive care unit setting.
  • Create awareness for limited outcome of standard of care treatment for pneumonia in the hospital.

Ophthalmology

  • Remote/mobile screening for Diabetic Retinopathy.
  • Remote monitoring of patients treated with anti-Vascular Endothelial Growth Factors (VEGFs).
  • Utilizing real-world evidence (RWE) to predict the need for anti-Vascular Endothelial Growth Factors (VEGFs)-injections.

Nephrology

  • Monitoring of chronic kidney disease (CKD).
  • Diagnosis of acute kidney injury.

Artificial Intelligence

  • Prediction of combination therapies for cancer.
  • Extract compound structures and Structure-Activity Relationship (SAR) data from patents.
  • Computer-assisted identification of new compounds for protein targets.
  • Develop analysis tool for in vivo experiments.

Data Analytics

  • Data analysis tools to systematically identify worldwide activities in Research & Development.
  • Deep Learning Research Services for health and life science data.
  • Transforming Electronic Health Records (EHR) data to analysis data sets.
  • Analyze drug labels to generate new insights.
  • Develop efficient analysis of large scientific literature corpi to generate insights.
  • How to implement prediction algorithms in hospital information systems.
  • Social Media use in pharma.

Clinical Trials

  • Patient identification and recruitment for clinical trials.
  • Improving the patient experience in clinical trials.
  • Develop a mobile platform for patients to report their health condition parameters.
  • Adherence improvement in (clinical trials OR) real life.

Submission deadline: 30 June 2017

For further information, please visit:
https://www.grants4apps.com/berlin/program/dealmaker-berlin-2017/

About Grants4Apps®
We connect health startups with industry experts and help the best talents to thrive within the digital healthcare universe. We are looking for startups beyond the ideation phase developing health technology or IT solutions that can connect and empower patients or healthcare stakeholders.

There are no boundaries to creativity!

Most Popular Now

Johnson & Johnson announces advance purchase a…

Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vacci...

Pfizer-BioNTech announce positive topline results …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SAR...

GSK to support manufacture of Novavax' COVID-19 va…

GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million doses of Novavax' COVID-19 va...

Pfizer and BioNTech confirm high efficacy and no s…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pi...

BioNTech provides update on vaccine production sta…

BioNTech SE today announced that the European Medicines Agency (EMA) approved the manufacturing of the COVID-19 vaccine drug product at the facility in Marburg. As part o...

COVID-19 convalescent plasma with greater antibody…

Convalescent plasma, the use of survivors' antibodies transfused into sick COVID-19 patients is safe and significantly improves clinical outcomes when using high levels o...

Undetected coronavirus variant was in at least 15 …

A highly contagious SARS-CoV-2 variant was unknowingly spreading for months in the United States by October 2020, according to a new study from researchers with The Unive...

New phase III data shows investigational antibody …

Roche (SIX: RO, ROG; OTCQX: RHHBY) confirmed positive topline results from the largest trial to date assessing a COVID-19 treatment in infected non-hospitalised patients ...

Valneva reports positive Phase 1/2 data for its in…

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical n...

Prioritizing who gets vaccinated for COVID-19 save…

Waiting for your turn can be frustrating, especially when it comes to COVID-19 vaccinations. But prioritizing who receives the limited supply of vaccines available saves ...

Clinical trial completion rates decline during COV…

Social distancing and lockdowns may have reduced the spread of COVID-19, but researchers from Penn State College of Medicine also report those actions may have affected c...

Study identifies possible COVID-19 drugs - includi…

A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has identified nine potential new COVID-19 treatments, including three that ...